ZELIRA THERAPEUTICS LIMITED
ASX:ZLDPharmaceuticals, Biotechnology & Life SciencesSuspended from quotationToday’s holders own 81.0% of what they think they own, once every option and right converts.
Not rated — the company is suspended from quotation
This company is suspended from ASX quotation. Scoring is paused until it resumes trading. Not rated means no assessment — not low risk.
ZELIRA THERAPEUTICS LIMITED's ordinary share count grew 10.5% between April 2025 and July 2026, reaching 13M shares. The company undertook one capital raise in the past 24 months, a A$500K convertible note issue in November 2025. Options and rights on issue represent a potential 3M new shares, which is 23.4% of the current share count; these are not currently in the money, and no expiry date is on record. As of June 2026, the company had A$4K in cash, covering approximately 0.0 quarters. No proposed securities issues are pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 2 July 2026 | 3H · cancellation | ZLD : ORDINARY FULLY PAID | 11.9M | Appendix 3H |
| 1 July 2026 | 2A · quoted issue | ZLD : ORDINARY FULLY PAID | 13.1M | Appendix 2A |
| 4 Dec 2025 | 3G · unquoted | ORDINARY FULLY PAID | 11.9M | Appendix 3G |
| 22 Oct 2025 | 3H · cancellation | ZLD : ORDINARY FULLY PAID | 11.9M | Appendix 3H |
| 1 Apr 2025 | 2A · quoted issue | ZLD : ORDINARY FULLY PAID | 11.9M | Appendix 2A |
Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (11.9M) need not equal the current count above (13.1M).
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered1.2M · 9.5% of sharesOptions and warrants — they convert when the share price clears their exercise price.No exercise price is on record for any of it, so none of it can be called in or out of the money.
- Converts on terms1.8M · 13.9% of sharesConvertibles with no exercise price — they convert on their own terms, so they are shares in all but name.
Exercise price on record: 0 priced, 3.1M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 3.1M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| ZLDAA | Options | Price-triggered | — | — | 1.2M | Filing |
| ZLDAM | Notes | Converts on terms | — | — | 1.8M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 1 July 2026 | Osagie Imasogie | Other | 1.3M | — | — | — | 3Y notice |
| 4 Dec 2025 | Dr. Donna Gentile O'Donnel | Other | — | 115k | 193k | $50k | 3Y notice |
| 4 Dec 2025 | Oludare Odumosu | Other | 132k | 240k | 387k | $100k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.